An anonymous director reports

SUPREME ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM

Supreme Pharmaceuticals Inc. is offering a limited-time incentive program commencing Feb. 16, 2016, to exercise 4,130,468 outstanding common share purchase warrants issued pursuant to the company's July 29, 2015, private placement (see news release dated July 30, 2015).

Pursuant to the incentive program, holders of the July warrants who exercise such warrants before March 17, 2016, shall, in addition to the common share the holder would have received pursuant to the terms of the July warrants, receive an additional common share purchase warrant. Each incentive warrant shall entitle the holder to purchase one common share of the company at an exercise price of 55 cents before July 27, 2018, subject to accelerated expiry in certain circumstances. The incentive warrants, and any common shares issuable upon the exercise thereof, will be subject to a four-month hold period from the date on which the incentive warrants are issued.

For any holder of a July warrant not participating in the incentive program, the July warrant shall continue to be exercisable in accordance with its terms. If a holder exercises only a portion of his or her July warrants pursuant to the incentive program, any unexercised July warrants shall continue to be exercisable in accordance with its terms.

We seek Safe Harbor.